Cytek Biosciences (CTKB) Invested Capital (2020 - 2026)

Cytek Biosciences has reported Invested Capital for 7 years, with the latest figure at $328.0 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital fell 13.8% year-over-year to $328.0 million; the trailing twelve-month figure through Mar 2026 stood at $328.0 million (down 13.8% YoY), and the FY2025 full-year result was $342.3 million, down 13.74% from the prior year.
• Invested Capital for Q1 2026 stood at $328.0 million, down from $342.3 million in the prior quarter.
• The five-year high for Invested Capital was $427.8 million in Q4 2022, with the low at $328.0 million in Q1 2026.
• Historically, Invested Capital has averaged $394.3 million across 5 years, with a median of $394.7 million in 2023.
• Annual changes were most pronounced in 2022 — Invested Capital jumped 36940.18% — and 2026, when it slipped 13.8%.
• Cytek Biosciences' Invested Capital stood at $427.8 million in 2022, then decreased by 7.74% to $394.7 million in 2023, then gained by 0.53% to $396.8 million in 2024, then fell by 13.74% to $342.3 million in 2025, then decreased by 4.16% to $328.0 million in 2026.
• The last three Invested Capital figures came in at $328.0 million (Q1 2026), $342.3 million (Q4 2025), and $379.2 million (Q3 2025), per Business Quant data.